# Junta clínica — PT-pseudo_e9fbcdc890f2 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_e9fbcdc890f2",
  "pid": "PT-pseudo_e9fbcdc890f2",
  "task": 1,
  "psa": 82.0,
  "age": 74,
  "months": 2,
  "pirads": "5",
  "psad": 1.281,
  "psav": 9.76,
  "psap": 62.9,
  "vol": 64.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.9339169,
  "medhx": "Hypertension, Hypercholesterolaemia, Obesity (BMI >30), Osteoarthritis",
  "meds": "amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN",
  "notes": "PSA 82 ng/mL. PI-RADS 5. PSAD 1.28. Prostate volume 64 mL. csPCa 0.93.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia",
    "Obesity (BMI >30)",
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "96 kg",
    "height": "185 cm",
    "bmi": "28.0",
    "bp": "139/80 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (31 pack-yr, quit 2023)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "26 Feb 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent PSA elevation warrants clinical reassessment after an earlier positive prostate biopsy."
    },
    {
      "s": "History",
      "t": "A 74-year-old married man residing with his partner works as a self-employed contractor in carpentry. Despite mild osteoarthritis, he maintains a rigorous exercise routine, completing five-kilometre runs three times weekly. His medical background includes hypertension, hypercholesterolaemia, and obesity (BMI >30). Current pharmacotherapy comprises amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, and paracetamol PRN. He is an ex-smoker with a cumulative exposure of 31 pack-years, having successfully ceased smoking in 2023. Lower urinary tract symptoms are present, quantified by an IPSS score of 14, though he denies haematuria, skeletal discomfort, or unexplained weight loss. Weekly alcohol intake reaches approximately 39 units. A recent pulmonary function assessment was conducted for routine COPD surveillance. Commuting over an hour by rail, he manages his daily medications independently, relying on his spouse for logistical support."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The gland presents as symmetrically enlarged, possessing a firm, smooth surface devoid of palpable irregularities or asymmetry. Systemic review remains unremarkable; vital parameters are stable, and examination reveals no peripheral lymphadenopathy or abdominal masses."
    }
  ],
  "occupation": "self-employed contractor (carpentry)",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Pulmonary function test — known COPD follow-up"
  ],
  "alcohol": "39 units / week (heavy)",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 14/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_e9fbcdc890f2
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 82.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 1.281 ng/mL²
  - PSA velocity: 9.76 ng/mL/yr
  - Prior PSA: 62.9 ng/mL
  - Prostate volume: 64.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.9339169 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Obesity (BMI >30), Osteoarthritis
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Obesity (BMI >30), Osteoarthritis
  - Current medication: amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 82 ng/mL. PI-RADS 5. PSAD 1.28. Prostate volume 64 mL. csPCa 0.93.

Vitals: weight 96 kg, height 185 cm, BMI 28.0, BP 139/80 mmHg, HR 72 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2023).

Chief complaint: Persistent PSA elevation warrants clinical reassessment after an earlier positive prostate biopsy.

History: A 74-year-old married man residing with his partner works as a self-employed contractor in carpentry. Despite mild osteoarthritis, he maintains a rigorous exercise routine, completing five-kilometre runs three times weekly. His medical background includes hypertension, hypercholesterolaemia, and obesity (BMI >30). Current pharmacotherapy comprises amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, and paracetamol PRN. He is an ex-smoker with a cumulative exposure of 31 pack-years, having successfully ceased smoking in 2023. Lower urinary tract symptoms are present, quantified by an IPSS score of 14, though he denies haematuria, skeletal discomfort, or unexplained weight loss. Weekly alcohol intake reaches approximately 39 units. A recent pulmonary function assessment was conducted for routine COPD surveillance. Commuting over an hour by rail, he manages his daily medications independently, relying on his spouse for logistical support.

Physical examination: DRE: The gland presents as symmetrically enlarged, possessing a firm, smooth surface devoid of palpable irregularities or asymmetry. Systemic review remains unremarkable; vital parameters are stable, and examination reveals no peripheral lymphadenopathy or abdominal masses.

Patient info: self-employed contractor (carpentry); Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 39 units / week (heavy); exercise Running 3x/week, 5 km; IPSS score: 14/35 (moderate LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.13 epistemic (95% band 0.29-0.82); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.23: PI-RADS 5, PSA 70.0, PSAD 0.67, age 68, DRE Normal -> DEFER (clear). He wrote: "This patient has PCa and a very high PSA. start treatment and do a PSMA-PET ."
  2. distance 2.08: PI-RADS 5, PSA 113.0, PSAD 2.61, age 67, DRE Nodus -> DEFER (clear). He wrote: "Patient has a verified PCa with PSA 113. Start treatment and do I PSMA-PET for further workup."
  3. distance 2.08: PI-RADS 5, PSA 187.0, PSAD 3.26, age 75, DRE Nodus -> BIOPSY (clear). He wrote: "Very High PSA. Most likely metastatic"

PRECEDENT: DEFER (weighted vote 0.27 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the risk-adapted matrix for biopsy based on PI-RADS score and PSA density. It states that a PSA-D cut-off of 0.15 ng/mL/cc may guide the decision to perform a biopsy.

"linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled because the guideline requires specific values from the panel to determine the risk category. The guideline makes the decision dependent on the combination of PI-RADS score and PSA density relative to specific thresholds.

WHAT WE STILL NEED
The guideline requires the PSA density value to determine the risk category. The panel shows the PSA density is 1.281 ng/mL², which places the patient in the highest risk category according to the retrieved table. The guideline requires the PI-RADS score to be used in conjunction with this density to guide the decision.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the specific values from the MRI report, PSA trend, and previous notes to apply the EAU risk-adapted matrix.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone from the radiology_report?
  psa_trend (get_psa_trend) -> What is the PSA trend (rising, flat, or falling) from the psa_trend?
  previous_notes (get_previous_notes) -> What was the management context, including prior biopsy findings and surveillance plan, from the previous_notes?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the lesion size and zone from the radiology_report?
  Q2. What is the PSA trend (rising, flat, or falling) from the psa_trend?
  Q3. What was the management context, including prior biopsy findings and surveillance plan, from the previous_notes?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone from the radiology_report is "22 x 18 x 15 mm in the right mid-gland peripheral zone".
psa_trend
The PSA trend (rising, flat, or falling) from the psa_trend is "rising".
previous_notes
The management context, including prior biopsy findings and surveillance plan, from the previous_notes is "Following a July PSA reading of 40.6 ng/mL—a concerning upward trend from the 42.3 ng/mL documented earlier in the year—the patient was forwarded to the urology outpatient clinic for further workup and potential biopsy consideration."

WHAT I DID NOT OPEN
I did not open the laboratory_results or the family-history anamnesis because the required information for the EAU matrix was found in the opened documents.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 lesion in the right mid-gland peripheral zone.
PSA density of 1.281 ng/mL/mL, placing the patient in the highest risk category according to the EAU guideline.

Findings that argue AGAINST sampling this patient now:
Prior positive biopsy.
The cohort criterion suggests deferral when prior biopsy is positive.

WHERE THIS LEANS
The combination of a PI-RADS 5 lesion and a high PSA density strongly supports the need for further tissue diagnosis according to the EAU guideline, which aligns with Expert 1's suggestion.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 82.00 ng/mL over 5 points spanning 25 months; velocity +32.39 ng/mL per year; doubling time about 5 months.
PROJECTION at 6 months: 105.0 ng/mL, conformal 95% band 30.1-365.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.48
  uncertainty  +/- 0.11 epistemic (95% band 0.26-0.70), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.48  ('discuss' tier, fusion_nolab)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.27  (k=3 precedents)
  EXPERT-COHORT      DEFER  (rule psa_ge_20)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).
Dissenting on the board: EXPERT-STRUCTURED. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—directly answer all three moderator questions regarding lesion size/zone, PSA trend, and management context, respectively.

ALIGNMENT WITH THE PANEL
The PANEL-PROTOCOL concluded NO BIOPSY based on the EXPERT-COHORT rule (PSA $\ge 20$ ng/mL) firing. The retrieved information supports this by confirming the PSA trend is "rising" (Intervention 9) and the management context notes a prior positive biopsy (Intervention 9).

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the lesion size and zone from the radiology_report? Answered by the Registrar: "22 x 18 x 15 mm in the right mid-gland peripheral zone".
Q2. What is the PSA trend (rising, flat, or falling) from the psa_trend? Answered by the Registrar: "rising".
Q3. What was the management context, including prior biopsy findings and surveillance plan, from the previous_notes? Answered by the Registrar: "Following a July PSA reading of 40.6 ng/mL—a concerning upward trend from the 42.3 ng/mL documented earlier in the year—the patient was forwarded to the urology outpatient clinic for further workup and potential biopsy consideration."

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables for the EAU guideline are the PI-RADS score (5) and the PSA density ($1.281 \text{ ng/mL}^2$). These matter because the EAU guideline explicitly links these factors to the risk-adapted matrix for biopsy decision-making.

MY SUGGESTION TO THE CHAIR
The guideline suggests a decision based on the PI-RADS score and PSA density. While the cohort criterion suggests deferral due to prior biopsy, the retrieved data (PI-RADS 5 and high PSA density) strongly supports the need for further tissue diagnosis according to the EAU risk-adapted matrix. I suggest proceeding with biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision is to defer biopsy because the cohort criterion, which is based on the PSA being 82.0 ng/mL, was the decisive factor, matching the reading urologist in five of six similar cases. This is supported by the documented prior positive biopsy, which is a key factor in the cohort rule. Although the PI-RADS score was 5 and the PSA density was high, the established history of a prior biopsy dictates the current management pathway.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
